US pharma company Alvogen has acquired five hormonal products from Germany's Bayer (DE: BAYN) in Russia and the Commonwealth of Independent States.
Alvogen has acquired Klimonorm (levonorgestrel ethinyl), Progynova (estradiol valerate), Triquilar (levonorgestrel and ethinylestradiol), Climene (estradiol) and Microgynon (ethinylestradiol and levonorgestrel) from Bayer. No financial terms of the deal were disclosed.
This strengthens and diversifies Alvogen’s branded portfolio in Central Eastern Europe.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze